All Recarbio articles
-
NewsWarning over lack of ‘substantial evidence’ for FDA approved antibiotic
Drugs approved in the US require “substantial evidence” that they are effective, but an investigation by The BMJ into the recent approval of the antibiotic Recarbrio from Merck suggests that these standards are being bypassed.
